Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ridaforolimus versus investigator's choice therapy in advanced endometrial carcinoma
2008-000634-53Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2008
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ridaforolimus in endometrial cancer (EC) (2 arms), sponsored by Merck & Co. Primary endpoint: Progression-free survival. Started Sep 2008; status: completed.
02
Drugs
ridaforolimus
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on 2008-000634-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000634-53.